HC Wainwright Reiterates “Buy” Rating for Chimerix (NASDAQ:CMRX)

Chimerix (NASDAQ:CMRX)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They currently have a $11.00 price target on the biopharmaceutical company’s stock.

A number of other research analysts have also recently commented on the stock. Wedbush reaffirmed an “outperform” rating and issued a $6.00 target price on shares of Chimerix in a research report on Thursday, November 7th. StockNews.com upgraded shares of Chimerix from a “sell” rating to a “hold” rating in a report on Wednesday, August 21st.

Chimerix Stock Performance

CMRX opened at $0.99 on Monday. The stock has a market capitalization of $88.96 million, a PE ratio of -1.06 and a beta of 1.13. Chimerix has a one year low of $0.75 and a one year high of $1.30. The business’s 50 day moving average price is $0.90 and its 200 day moving average price is $0.91.

Chimerix (NASDAQ:CMRX) last announced its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.23) EPS for the quarter, meeting the consensus estimate of ($0.23). The business had revenue of $0.13 million during the quarter, compared to analyst estimates of $1.26 million. During the same period last year, the company earned ($0.21) EPS. As a group, equities research analysts forecast that Chimerix will post -0.91 earnings per share for the current fiscal year.

Institutional Trading of Chimerix

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Koshinski Asset Management Inc. acquired a new position in shares of Chimerix in the first quarter valued at approximately $42,000. Valeo Financial Advisors LLC grew its stake in shares of Chimerix by 566.9% in the third quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 69,505 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of Chimerix during the second quarter worth $137,000. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Chimerix by 66.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock valued at $321,000 after purchasing an additional 138,098 shares during the period. Finally, Acadian Asset Management LLC boosted its holdings in Chimerix by 15.5% in the first quarter. Acadian Asset Management LLC now owns 2,174,813 shares of the biopharmaceutical company’s stock valued at $2,304,000 after purchasing an additional 291,981 shares during the period. 45.42% of the stock is currently owned by hedge funds and other institutional investors.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.